• Boc-D-FMK for Apoptosis and Inflammation Workflows

  2026-08-23

  Boc-D-FMK provides a cell-permeable, irreversible pan-caspase blockade for separating caspase-dependent death from inflammatory signaling. This practical guide connects controlled cell assays with renal endothelial inflammation and hepatocyte apoptosis models while showing how to interpret results alongside the CYP2B6 glioblastoma findings.

• LL-37 Fragments Against MDR A. baumannii

  2026-08-22

  The 2013 reference study systematically compared LL-37 and three derived fragments, including KR-12, against multidrug-resistant Acinetobacter baumannii. Its key contribution was showing that rapid bacterial killing, inhibition of surface adherence, and activity against established biofilms are related but distinct peptide effects that should be measured separately.

• CCT007093: A Practical PPM1D Inhibitor Workflow

  2026-08-21

  CCT007093 connects biochemical PPM1D inhibition with measurable P38 kinase activation, cell viability changes, and pyroptosis-associated readouts. This workflow shows how to use the compound in breast cancer and kidney injury models while controlling for DMSO exposure, timing, and pathway-dependent cytotoxicity.

• TMAO–PERK Signaling in NAFLD: Study Analysis

  2026-08-21

  A 2024 Toxicology Letters study used dietary TMAO exposure in zebrafish and complementary liver-cell models to show that TMAO can directly promote steatosis, inflammation, liver injury, and fibrosis alongside PERK-pathway activation. The work strengthens a mechanistic link between a gut microbiota-derived metabolite and NAFLD progression, while also defining experimental opportunities to test whether PERK activation is causally required.

• LLY-507: A Practical SMYD2 Inhibitor Workflow

  2026-08-20

  LLY-507 combines nanomolar biochemical potency with strong selectivity, making it useful for separating SMYD2-dependent signaling from broad methyltransferase effects. This guide translates the compound into reproducible cancer, apoptosis, and renal-fibrosis assay workflows while highlighting the limits of preclinical interpretation.

• SOAT1, Lipophagy, and PHMG-Induced Lung Fibrosis

  2026-08-20

  The reference study identifies SOAT1 as a previously unrecognized mediator of PHMG-induced pulmonary fibrosis, linking alveolar-macrophage cholesterol esterification to defective lipophagy and foam-cell formation. Its mouse, macrophage, and pharmacological data position SOAT1 inhibition with avasimibe as a preclinical strategy, while also providing a framework for studying lipid dysregulation in fibrotic lung disease.

• MK-8745: Aurora A Inhibitor for Cancer Assays

  2026-08-19

  MK-8745 provides a practical route to connect Aurora A activity with mitotic arrest, apoptosis, and tumor-model response. This workflow-oriented guide shows how to apply the compound across cancer cell lines, non-Hodgkin lymphoma studies, and retinoblastoma-focused translational assays while controlling for solubility and p53-context effects.

• 2X HyperFusion High-Fidelity Master Mix for PCR

  2026-08-19

  Build cloning, construct-validation, and mutation-sensitive PCR workflows around fast, accurate amplification with blunt-ended products. This guide connects the mix to practical assay planning inspired by a CRISPR/Cas9 nanomedicine study while clearly separating published findings from recommended PCR starting conditions.

• NAT10–OGA ac4C Control of Oocyte Maturation

  2026-08-18

  Lin et al. identify OGA mRNA as a functional target of NAT10-mediated N4-acetylcytidine (ac4C) modification during mouse oocyte maturation. The study links RNA modification and O-GlcNAc metabolism, showing that NAT10 supports OGA transcript stability and that OGA is required for efficient in vitro maturation (IVM).

• Dye Models for Small Tissue Biopsies in Pathology

  2026-08-18

  The reference study evaluated five dyes as visual markers for small biopsy fragments during tissue preparation and found that merbromin, hematoxylin, and Alcian blue improved tissue observability. Hematoxylin was favored because it combined useful visibility with lower toxicity and no apparent interference during routine slide examination.

• Vardenafil HCl Trihydrate in PDE5 Research

  2026-08-17

  Vardenafil HCl Trihydrate combines nanomolar PDE5 potency with a selectivity profile suited to enzyme, cellular, smooth muscle, and erectile dysfunction model workflows. Its strongest differentiation emerges when conventional cGMP assays are paired with native-environment proteoform analysis to examine PDE6-related off-target interactions.

• Romidepsin (FK228) for HDAC Research Workflows

  2026-08-16

  Romidepsin, also called FK228, combines selective class I HDAC activity with practical applications in chromatin, apoptosis, and DNA-repair research. This workflow-focused guide shows how to connect viability data with SmD2 acetylation, alternative splicing, and PARP-inhibitor sensitivity in hepatocellular carcinoma models.

• Gastrodin, RAS–SIRT3, and Reactive Astrocytes

  2026-08-15

  The reference study shows that microglia-derived signals can activate a renin–angiotensin system (RAS)–SIRT3 program in astrocytes and alter inflammatory and neurotrophic markers. Its use of gastrodin and the AT1 inhibitor azilsartan separates pathway modulation from broader microglia-conditioned effects, while also highlighting important limits of simplified cell models.

• ONX-0914 (PR-957) for LMP7 Research

  2026-08-15

  ONX-0914 (PR-957) enables selective LMP7-centered experiments that connect immunoproteasome biology with cytokine control, autoimmune disease models, and airway inflammation. This practical guide covers assay design, dose selection, workflow controls, and troubleshooting so researchers can distinguish genuine target-dependent effects from toxicity or broader proteasome inhibition.

• Medroxyprogesterone Acetate: Research Workflows

  2026-08-14

  Build reproducible MPA experiments across renal, reproductive, and neurobiology models with solvent-aware dosing and pathway-specific readouts. The workflow also shows how to use the compound alongside vitamin D/VDR decidualization assays without confusing a progestin perturbation with a vitamin D mechanism.

466 records 8/32 page Previous Next First page 上5页 678910 下5页 Last page